Abstract
The Icatibant Outcome Survey (IOS; NCT01034969) monitors icatibant safety and effectiveness in a real-world setting. While icatibant is licensed in numerous countries for hereditary angioedema (HAE) attacks in adults with C1-INH deficiency, we report IOS data for off-label use in angioedema due to acquired C1-INH deficiency. This condition shares a mechanism and clinical profile with HAE, but is less prevalent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.